Neogen Chemicals Approves Audited Results, Recommends Dividend of ₹1/Share
Neogen Chemicals approved its audited standalone and consolidated financial results for FY26. The Board recommended a final dividend of ₹1 per share. Project timelines and costs for its subsidiary, Neogen Ionics Limited, were revised, with Dahej Phase 1 at ₹428 crore (Feb 2027) and Pakhajan Phase 2 at ₹1,367 crore (Mar 2027).
The dividend recommendation and the approval of financial results are important for investors. The revised project timelines and costs for the subsidiary also warrant attention.
The approval of audited financial results and the recommendation of a dividend are positive indicators for the company.
Neogen Chemicals Limited announced the outcome of its Board Meeting held on May 16, 2026. The Board approved the audited financial results for the quarter and financial year ended March 31, 2026, both on a standalone and consolidated basis. The company's statutory auditors, M/s. Chandabhoy & Jassoobhoy, have issued an unmodified audit opinion on these results.
Additionally, the Board recommended a final dividend of ₹1 per equity share for the Financial Year 2025-26, subject to shareholder approval at the upcoming 37th Annual General Meeting (AGM). The record date for the dividend and the AGM date will be intimated in due course.
The company also reported updates on its wholly-owned subsidiary, Neogen Ionics Limited (NIL). The revised projected cost for the Dahej Phase 1 project is ₹428 crore with a timeline of February 2027, and for the Pakhajan Phase 2 project, it is ₹1,367 crore with a timeline of March 2027. These revisions are due to design optimization and higher localization of sub-components. The total revised cost for these projects amounts to ₹1,795 crore.
Furthermore, amendments to "the Code for prevention of insider trading in the securities of Neogen Chemicals Limited" were approved and uploaded on the company's website. Details of outstanding and incremental qualified borrowings for FY 2025-26 were also provided.
What to do with a filing like this
Neogen Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Neogen Chemicals Limited. Read the original for the full detail.